ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.